Thus, Fli-1 transactivating compounds may cooperate with Imatinib for the treatment of chronic myelogenous leukemia (CML) driven by BCR-ABL. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.